Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Jiangxi Jiangzhong Pharmaceutical Enters Distribution Business

This article was originally published in PharmAsia News

Executive Summary

Jiangxi Jiangzhong Pharmaceutical, China's leading OTC drug company, will acquire stakes in Jointown Group's subsidiary Jiangxi Jointown Pharmaceutical with 11.18 million yuan (1.62 million). At the same time, it will pump in 18.8 million yuan ($2.73 million) to increase its equity in Jiangxi Jointown, securing 51 percent of the firm in total. Analysts say the move will expand the marketshare of Jiangzhong Pharmaceutical's brand and products to gain a dominant position in Jiangxi. Jointown can bring complementary products into the region and develop its end-user market through the collaboration. Observers note the trend of pharmaceutical companies entering drug distribution to control the end-user retail market will have significant impact on the domestic industry. (Click here for more - Chinese Language)

You may also be interested in...

P&G Tapping Into UK Vegan Trend Via Nature’s Best

Procter & Gamble, through its UK wellness subsidiary Nature's Best, is on-trend with new vegan vitamin D3 and iron supplements. Nature's Best has also launched three other vitamin D3 products in the country, as well as an ashwagandha supplement. 

UK Shares How Its Medtech Regs Already Diverge From The EU: COVID-19 Marks The Start

The MHRA has updated its guidance on regulatory flexibilities for medical devices and medicinal products resulting from COVID-19 to highlight how its approach differs from the EU.

Carag Applies Bioabsorbable Material Technology To Transseptal Occluders

The Swiss company is planning a US trial of CBSO, the first transcatheter septal occluder with a bioresorbable, metal-free frame.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts